TY - JOUR
T1 - Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis
T2 - a European routine-care observational study
AU - Christiansen, Sara Nysom
AU - Rasmussen, Simon Horskjær
AU - Ostergaard, Mikkel
AU - Pons, Marion
AU - Michelsen, Brigitte
AU - Pavelka, Karel
AU - Codreanu, Catalin
AU - Ciurea, Adrian
AU - Glintborg, Bente
AU - Santos, Maria Jose
AU - Sari, Ismail
AU - Rotar, Ziga
AU - Gudbjornsson, Bjorn
AU - Macfarlane, Gary J.
AU - Relas, Heikki
AU - Iannone, Florenzo
AU - Laas, Karin
AU - Wallman, Johan K.
AU - van de Sande, Marleen
AU - Provan, Sella Aarrestad
AU - Castrejon, Isabel
AU - Zavada, Jakub
AU - Mogosan, Corina
AU - Nissen, Michael J.
AU - Loft, Anne Gitte
AU - Barcelos, Anabela
AU - Erez, Yesim
AU - Pirkmajer, Katja Perdan
AU - Grondal, Gerdur
AU - Jones, Gareth T.
AU - Hokkanen, Anna Mari
AU - Chimenti, Maria Sole
AU - Vorobjov, Sigrid
AU - Giuseppe, Daniela Di
AU - Kvien, Tore K.
AU - Otero-Varela, Lucia
AU - van der Horst-Bruinsma, Irene
AU - Hetland, Merete Lund
AU - Ørnbjerg, Lykke Midtbøll
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
PY - 2024
Y1 - 2024
N2 - Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
AB - Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
KW - Ankylosing
KW - Epidemiology
KW - Pain
KW - Patient Reported Outcome Measures
KW - Spondylitis
KW - Therapeutics
U2 - 10.1136/rmdopen-2024-004166
DO - 10.1136/rmdopen-2024-004166
M3 - Journal article
C2 - 39053949
AN - SCOPUS:85199661747
VL - 10
JO - RMD Open
JF - RMD Open
SN - 2056-5933
IS - 3
M1 - e004166
ER -